Last €0.80 EUR
Change Today +0.053 / 7.07%
Volume 1.5K
As of 11:27 AM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (VPA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - €1.40
52 Week Low
12/11/14 - €0.46
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

aveo pharmaceuticals inc (VPA) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (VPA) Details

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent’s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co., Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

71 Employees
Last Reported Date: 03/13/14
Founded in 2001

aveo pharmaceuticals inc (VPA) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $351.1K
Executive Officer
Total Annual Compensation: $334.5K
Compensation as of Fiscal Year 2013.

aveo pharmaceuticals inc (VPA) Key Developments

Matthew Dallas, Vice President, Finance, Treasurer and the Principal Accounting Officer Leaves AVEO Pharmaceuticals, Inc., Effective February 6, 2015

On January 19, 2015, Matthew Dallas, Vice President, Finance, Treasurer and the principal accounting officer of AVEO Pharmaceuticals, Inc. announced that he will be leaving the company on February 6, 2015 to pursue a new career opportunity.

AVEO Oncology Appoints Michael N. Needle as Chief Medical Officer

AVEO Oncology announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the company’s partnered and proprietary pipeline programs. He will report to Michael Bailey, the company’s president and chief executive officer. He most recently served as the Chief Medical Officer of Array BioPharma.

AVEO Pharmaceuticals, Inc. Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency

AVEO Pharmaceuticals, Inc. has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agencyâ s centralized procedure. Confirmation of eligibility was given in response to the submission of a letter of intent enabling the Company to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for tivozanib with the EMA for the treatment of renal cell carcinoma (RCC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors. Tivozanib has previously been granted orphan drug designation in Europe for the treatment of RCC. The letter of intent, which must be filed at least seven months prior to submission of a MAA, initiates the process to address a number of pre-submission requirements, including the assignment of a Rapporteur and Co-Rapporteur, who are two appointed members of the Committee for Human Medicinal Products (CHMP). The CHMP is the committee responsible for preparing opinions on questions concerning human medicines. Confirmation of eligibility for submission is not predictive of the EMAâ s approval of a MAA. AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in RCC and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. AVEO recently entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye, and the Company is actively pursuing partnerships to advance the development of tivozanib in solid tumors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPA:GR €0.80 EUR +0.053

VPA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.97 USD +0.32
Bristol-Myers Squibb Co $61.46 USD +0.24
Exelixis Inc $2.93 USD +0.24
GlaxoSmithKline SAE £11.70 EGP -0.30
Takeda Pharmaceutical Co Ltd ¥6,104 JPY -4.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VPA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at